U.S. PRODUCERS' QUESTIONNAIRE

METHYLENE DIPHENYL DIISOCYANATE ("MDI") PRODUCTS FROM CHINA

This questionnaire must be received by the Commission by <u>February 26, 2025.</u>

See last page for instructions regarding how to file this questionnaire.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping duty investigation concerning MDI products from China (Inv. No. 731-TA-1733 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

City	State	Zip Code	
Website			
Has your firm produce 2022?	ed MDI products (as defined on next pag	ge) in the United States	at any time since January 1,
NO (Sign th	e certification below and promptly return o	nly this page of the quest	ionnaire to the Commission)
YES (Comple	ete all parts of the questionnaire, and retur	n the entire questionnaire	e to the Commission)
that the information he	CERTIFICATI rein supplied in response to this questi		d correct to the best of my kno
ief and understand that ition I also grant consent	CERTIFICATI rein supplied in response to this questi the information submitted is subject to t for the Commission, and its employee out this proceeding in any other impo	onnaire is complete an o audit and verification es and contract person	n by the Commission. By means nel, to use the information prov
ief and understand that ation I also grant consent astionnaire and through a similar merchandise. Indersigned, acknowledging or other proceeding and evaluations relating by U.S. government en	rein supplied in response to this questi the information submitted is subject to t for the Commission, and its employee	onnaire is complete and audit and verification is and contract person ort-injury proceedings conse to this request by the Commission, its related proceeding, or rations of the Commissions	n by the Commission. By means nel, to use the information prov conducted by the Commission for information and througho employees and Offices, and co (b) in internal investigations, sion including under 5 U.S.C. Ap
ief and understand that ation I also grant consent astionnaire and through a similar merchandise. Indersigned, acknowledging or other proceeding and evaluations relating by U.S. government en	rein supplied in response to this questi the information submitted is subject to t for the Commission, and its employee out this proceeding in any other impo ge that information submitted in resp as may be disclosed to and used: (i) be a maintaining the records of this or a ag to the programs, personnel, and open apployees and contract personnel, sole	onnaire is complete and audit and verification is and contract personing ort-injury proceedings to this request by the Commission, its related proceeding, or rations of the Commission by for cybersecurity pu	n by the Commission. By means nel, to use the information prov conducted by the Commission for information and througho employees and Offices, and co (b) in internal investigations, sion including under 5 U.S.C. Ap

PART I.—GENERAL INFORMATION

<u>Background.</u>-- This proceeding was instituted in response to a petition filed on February 12, 2025, by the MDI Fair Trade Coalition consisting of BASF Corporation, Florham Park, New Jersey; and The Dow Chemical Company, Midland, Michigan. Antidumping duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of dumping. Pertinent information to this proceeding is available at:

Questionnaires: https://usitc.gov/reports/active import injury questionnaires. Other case information: https://ids.usitc.gov/case/8267/investigation/8705

MDI products covered by this petition is aromatic polyisocyanate material whose composition includes two or more isocyanate groups (i.e., functional group containing a nitrogen atom, a carbon atom, and an oxygen atom bonded together (-NCO)) attached to one or more benzene rings (i.e., flat, symmetrical molecule made up of six carbon atoms arranged in a hexagonal ring and has the chemical formula C6H6) that are joined by methylene bridges (i.e., a carbon atom bound to two hydrogen atoms (-CH2-) and connected by single bonds to two other distinct atoms in the rest of the molecule). These products are commonly called Polymeric, Monomeric, or Modified Methylene Diphenyl Diisocyanate ("MDI") and also known as Methylene bisphenyl isocyanate, 4,4'-Diphenylmethane diisocyanate, Methylene di-phenylene ester of isocyanic acid, Methylene bis(4-phenyl isocyanate), among others. MDI is normally associated with Chemical Abstracts Service ("CAS") registry numbers 9016-87-9, 101-68-8, 5873-54-1, 2536-05-2, 2536-05-2, 25686-28-6, 26447-40-5, and 39310-05-9, but several others are also used.

MDI ranges in physical form from low viscosity liquids to solids. MDI is covered by the scope of this petition irrespective of whether it has gone through a distillation process and regardless of acid content, reactivity, functionality, freeze stability, physical form, viscosity, grade, purity, molecular weight, or packaging.

MDI may contain additives, such as catalysts, solvents, plasticizers, antioxidants, fire retardants, colorants, pigments, diluents, thickeners, fillers, softeners, toughening agents. The scope does not include mixtures of MDI with other materials, when the combined MDI component comprises less than 40 percent of the total weight of the mixture.

MDI may be partially reacted with itself, polyol, or polyamines, and retain MDI component that has not fully chemically reacted so as to convert it into a different product no longer containing isocyanate groups. These products are known as homopolymer, uretonimine MDI, carbodiimide MDI, or prepolymers. The scope does not include partially reacted MDI when its NCO content is less than 10 weight percentage.

For MDI that enter as part of a system with separately packaged polyol, only the MDI portion of the system is included in the scope. The scope does not include any separately packaged polyol that would not fall within the scope if entered on its own.

The scope includes merchandise matching the above description that has been processed in a third country, including by commingling, diluting, introducing or removing additives, or performing any other processing that would not otherwise remove the merchandise from the scope of the investigations if performed in the subject country.

The scope also includes MDI that is commingled or blended with MDI from sources not subject to this investigation. Only the subject component of such commingled products is covered by the scope of this investigations.

This merchandise is currently classifiable under Harmonized Tariff Schedule of the United States (HTSUS) subheadings 2929.10.8010 and 3909.31.0000. Subject merchandise may also be entered under subheadings 3909.50.5000, 3824.99.2900, 3824.99.9397, 3506.91.5000, 3815.90.5000, 3911.90.4500, 3921.13.5000, 3920.99.5000. The HTSUS subheadings are provided for convenience and customs purposes only; the written description of the scope is dispositive.

<u>Reporting of information</u>.--If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

Release of information. -- The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals. In addition, if your firm is a U.S. producer, the information you provide on your production and imports of MDI products and your responses to the questions in Part I of the producer questionnaire will be provided to the U.S. Department of Commerce, upon its request, for use in connection with (and only in connection with) its requirement pursuant to section 702(c)(4)/732(c)(4) of the Act (19 U.S.C. § 1671a(c)(4)/1673a(c)(4)) to make a determination concerning the extent of industry support for the petition requesting this proceeding. Any information provided to Commerce will be transmitted under the confidentiality and release guidelines set forth above. Your response to these questions constitutes your consent that such information be provided to Commerce under the conditions described above.

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is <u>optional</u>. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1a. Reporting requirements.--Please report below the actual number of hours required and the cost to your firm of completing this questionnaire for use by the Office of Management and Budget.

Hours	Dollars

Public reporting burden for this questionnaire is estimated to average 55 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please provide such comments to the Office of Investigations, import_injury@usitc.gov.

I-1b.	TAA information release In the event that the U.S. International Trade Commission (USITC)
	makes an affirmative final determination in this proceeding, do you consent to the USITC's
	release of your contact information (company name, address, contact person, contact person's
	title, telephone number, email address) appearing on the front page of this questionnaire to the
	Departments of Commerce, Labor, and Agriculture, as applicable, so that your firm and its
	workers can be made eligible for benefits under the Trade Adjustment Assistance program?

Yes		Nο

I-2a. <u>Type of operations</u>.--Please identify which type of operations your firm conducts below.

Type of operations	Description (check all that apply)	
Production	Your firm purchases, produces, or otherwise procures upstream out-of-scope chemical inputs (e.g., aniline and formaldehyde/formalin) that it then uses them to produce methylene diphenyl diisocyanate via a chemical reaction. Your firm may or may not also conduct further processing, including mixing or blending your own U.Sproduced methylene diphenyl diisocyanate into other MDI products.	
Processing	Your firm purchases or otherwise procures in-scope MDI products <u>from another entity</u> (i.e., either domestically manufactured or imported MDI products), and your firm conducts further processing of those already in-scope MDI products into another form of in-scope product (e.g., import crude polymeric MDI and process it into pure monomeric MDI) in the United States.	
¹ The primary chemical reaction is one that reacts two or more chemical compounds to yield an MDI products in its pure form (e.g., without additions)		

in its pure form (e.g., without additives).

Note: If your firm both produces MDI products domestically as well as processes imported or purchased MDI products (i.e., conducts domestic activities on purchased MDI products that your firm itself has produced), please separately report on those operations (i.e., production operations in parts II and III, and processing operations in part VII). The following schematic reflects how the Commission is asking firms to report their operations in this questionnaire.

Item	Production operations with or without additional processing	Processing operations using purchased or imported MDI products
Part I: General information		
Part II: Trade and related information		
Part III: Financial information	$\overline{\square}$	
Part IV: Pricing and market factors		
Part V: Alternative product information	\square	\square
Part VI: Sufficient production related activities		Ø
Part VII: Processing operations		

I-2b. <u>Establishments covered</u>.--Provide the city, state, zip code, and brief description of each establishment covered by this questionnaire. Firms operating more than one establishment should combine the data for all establishments into a single report.

"<u>Establishment</u>"--Each facility of a firm involved in the <u>production</u> of MDI products, including auxiliary facilities operated in conjunction with (whether or not physically separate from) such facilities.

Establishments covered ¹	City, State	Zip (5 digit)	Description		
1					
2					
3					
4					
5					
6					
¹ Additional disc	¹ Additional discussion on establishments consolidated in this questionnaire:				

I-2c.	Stock symbol information If your firm or parent firm is publicly traded, please specify the
	stock exchange and trading symbol:

I-2d. <u>External counsel.</u>— If your firm or parent firm is represented by external counsel in relation to this proceeding, please specify the name of the law firm and the lead attorney(s).

Law firm:	
Lead attorney(s):	

I-3. <u>Petitioner status.</u>--Is your firm a petitioner in this proceeding or a member firm of the petitioning entity?

No	Yes

I-4. Petition support.--Does your firm support or oppose the petition?

Country	Investigation type	Support	Oppose	Take no position
China	Antidumping duty			

U.S. Producers' Questionnaire – MDI Products (Preliminary) Page 7 **Ownership**.--Is your firm owned, in whole or in part, by any other firm? I-5. Yes--List the following information, relating to the ultimate parent/owner. ☐ No Extent of ownership Firm name Country (percent)

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

5.	foreign, that are engage		related firms, either domestic or no china into the United States or that e United States?
	☐ No ☐ Yes-	-List the following information.	
	Firm name	Country	Affiliation
	□ No □ Yes-	-List the following information. Country	Affiliation
	rii ii iiaiiie	Country	
			Annation
			Annation
			Amilation
			Ammation
			Ammation

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Lawrence Jones (202-205-3358, lawrence.jones@usitc.gov). Supply all data requested on a calendar-year basis.

II-1.	<u>Contact information</u> Please identify the responsible individual and the manner by which
	Commission staff may contact that individual regarding the confidential information submitted
	in Part II.

Name	
Title	
Email	
Telephone	

II-2a. <u>Changes in operations.</u>--Please indicate whether your firm has experienced any of the following changes in relation to the production of MDI products since January 1, 2022.

Check as many as appropriate.		If checked, please describe the nature, timing / duration, and impact on operations of any such reported changes as well as the business reasons for them; leave completely blank if not applicable
	Plant openings	
	Plant closings	
	Prolonged shutdowns	
	Production curtailments	
	Relocations	
	Expansions	
	Acquisitions	
	Consolidations	
	Weather-related or force majeure events	
	Other (e.g., revised labor agreements, technology)	

II-3a. **Production using same machinery.--**Please report your firm's production of products using the same equipment, machinery, or employees as used to produce MDI products, and the combined capacity (both installed and practical capacity) on this shared equipment, machinery, or employees in the periods indicated.

"Installed overall capacity" – The level of production that your establishment(s) could have attained, assuming your firm's optimal product mix, and based solely on existing capital investments, i.e., machinery and equipment that is in place and ready to operate. This capacity measure does <u>not</u> take into account other constraints to production such as existing workforce constraints, availability of raw materials, or downtime for maintenance, repair, and cleanup. This capacity measure is sometimes referred to as "nameplate" or "theoretical" capacity.

"Practical overall capacity" – The level of production that your establishment(s) could reasonably have expected to attain, taking into account your firm's actual product mix over the period. This capacity measure is based on not only existing capital investments, i.e., machinery and equipment that is in place and ready to operate; but also non-capital investment constraints, such as (1) normal operating conditions, including normal downtime for maintenance, repair, and cleanup; (2) your firm's existing in place and readily available labor force; (3) availability of material inputs; and (4) any other constraints that may have limited your firm's ability to produce the reported products. Importantly, this capacity measure is the maximum "practical" production your firm could have achieved without hiring new personnel or expanding the number of shifts operated in the period.

"Practical MDI products capacity" – The level of production of MDI products that your establishment(s) could reasonably have expected to attain. The same assumptions apply to this capacity measure as for practical overall capacity, but only includes the portion of practical overall capacity allocated to the production of MDI products based on the actual product mix experienced over the period.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

Takes into account	Installed overall capacity	Practical overall capacity	Practical MDI products capacity
Existing capital investments	Yes	Yes	Yes
Product mix	Yes	Yes	Yes
Normal downtime, maintenance, repair and clean-up	No	Yes	Yes
Existing labor force	No	Yes	Yes
Availability of material inputs	No	Yes	Yes
Actual number of shifts and hours operated	No	Yes	Yes
Limited to MDI products	No	No	Yes

II-3a. **Production using same machinery.--Continued**

Quantity (in short tons)			
	Calendar year		
ltem	2022	2023	2024
Capacity measures: Installed overall capacity ¹			
Practical overall capacity ¹²			
Practical MDI products capacity ^{3 4}	0	0	0
Production of: MDI products ^{3 4}	0	0	0
Other out-of-scope products: Toluene di-isocyanate (TDI) products			
Other products ⁵			
Subtotal, all out-of-scope products	0	0	0
Total production using same machinery or workers	0	0	0

¹ Data reported for both "installed overall" and "practical overall" capacity should each individually be greater than data reported for total production (last line). Additionally, data reported for "installed overall" capacity should be greater than "practical overall" capacity in every period.

² Please provide details in your response to the question on capacity constraints in question II-3d below that explain the differences reported between "installed" overall capacity and "practical" overall capacity.

³ Data for this indicator will populate here once reported below in question II-8.

⁴ Data reported for practical MDI products capacity should be greater than the data reported for production of MDI products in each period, if not revise prior to submission to the Commission. Additionally, if your firm reports the production of no other products on the same machinery and using the same workers as MDI products then "practical overall" and "practical MDI products" capacity measures should be equal to each other.

⁵ Please identify these products: _____.

U.S. Producers' Questionnaire - MDI Products (Prelimin	ary)
--	------

Hours por wook	Wooks por year	
Hours per week	Weeks per year	
Capacity calculationsPlease de	escribe the methodology used	to calculate <i>installed</i> and <i>pro</i>
	<u>.</u>	changes in reported capaciti

II-3d. Practical overall capacity constraints.--Please describe the constraint(s) that set the limit(s) on your firm's practical overall capacity over the period reported in question II-3a. If different constraints were binding over different periods reported, please specify when each constraint was limiting your reported practical overall capacity. If a constraint was not actually binding over the period reported, but was still a constraint to achieving the installed capacity level, indicate at what level it would have been binding.

Constraint (check as many as appropriate)		Description (If checked, please describe the details, timing, and duration of the constraint; leave completely blank if not applicable)
	Production bottlenecks	
	Existing labor force	
	Supply of material inputs	
	Fuel or energy	
	Storage capacity	
	Logistics/transportation	
	Other constraints (list the specific constraints in the description field)	

Reaching installed overall capacity. -- Please describe and quantify the amount of time it would take II-3e. and the additional actions that would be needed (e.g., hiring new workers, expanding shifts, procuring larger sources of raw material supply, etc.) for your firm to be able to fully utilize the reported installed overall capacity reported in II-3a. II-3f. Excess installed overall capacity. -- To the extent that your company is reporting excess installed overall capacity, please report, with specificity: (1) which machines or equipment (or other elements of production) would need to be brought back into production for your plant to operate at full capacity, and (2) the specific dates on which such machines or equipment were last used by your plant to produce MDI products. II-4. Product shifting.--Is your firm able to switch production (capacity) between MDI products and other products (a) using the same equipment and/or labor? If yes—(i.e., have produced other products or are able to produce other No Yes products) Please identify other actual or potential products. (b) Please describe the factors that affect your firm's ability to shift capacity between products (e.g., time, cost, relative price change, etc.), and the degree to which these factors enhance or constrain such shifts.

II-5. <u>Capacity checklist.</u>--Please check that the capacity numbers reported in question II-3a follow the Commission's relevant definitions for capacity.

Item	√ if Yes
Are all three capacity measures reported based on <u>currently installed</u> <u>machinery and equipment</u> (i.e., the reported capacity level would not require additional capital investments in order to achieve)?	
Are practical overall capacity and practical MDI products capacity measures reported based on <u>existing labor force</u> (i.e., the reported capacity level would not require hiring additional production related workers or adding shifts)?	
Are practical overall capacity and practical MDI products capacity measures based on the actual availability of material inputs?	
Do both practical overall capacity and practical MDI products capacity measures account for <u>normal downtime, maintenance, repair and cleanup</u> activities?	
Does the difference between practical overall capacity and practical MDI products capacity equal the portion of practical overall capacity that is dedicated to the production of out-of-scope products?	

Note: If your firm is not able to answer "yes" to any of the above criteria as it relates to your firm's reported capacity levels, please revise your capacity numbers to be in conformance with the appropriate definition prior to submission to the Commission.

II-6. **Tolling**.--Since January 1, 2022, has your firm been involved in a toll agreement regarding the production of MDI products?

"Toll agreement"-- Agreement between two firms whereby the first firm ("tollee") furnishes the raw materials and the second firm ("toller") uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

No	Yes	
		If yes—Please complete the table below.

Does your firm act as the toller or tollee in this arrangement?	Toller:	Tollee:
Report the share of your firm's production of MDI products that watchis toll arrangement in 2024.	as included in	%
Please describe the activities performed in this tolling arrangement	t:	
Please indicate the name(s) of the firm(s) involved:		

II-7.	Foreign	trade	zones

(a) <u>Firm's FTZ operations</u>.--Does your firm produce MDI products in and/or admit MDI products into a foreign trade zone (FTZ)?

"Foreign trade zone" is a designated location in the United States where firms utilize special procedures that allow delayed or reduced customs duty payments on foreign merchandise. A foreign trade zone must be designated as such pursuant to the rules and procedures set forth in the Foreign-Trade Zones Act.

No	If yesDescribe the nature of your firm's operations in FTZs and identify the specific FTZ site(s).

(b) Other firms' FTZ operations.--To your knowledge, do any firms in the United States import MDI products into a foreign trade zone (FTZ) for use in distribution of MDI products and/or the production of downstream articles?

No	Yes	If yesIdentify the firms and the FTZs.	

II-8. **Production, shipments, and inventory data.-**-Report your firm's practical capacity, production, shipments, and inventories of domestically produced MDI products during the specified periods.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

"Commercial U.S. shipments" – Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories"— Processed goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-8. Production, shipment, and inventory data.--Continued

		Calendar yea	ar
Item	2022	2023	2024
Practical MDI products capacity ¹ (quantity) (A)			
Beginning-of-period inventories (quantity) (B)			
Production (quantity) (C)			
U.S. shipments: Commercial shipments: Quantity (D)			
Value (E)			
Internal consumption: ² Quantity (F) Value ² (G)			
Transfers to related firms: ² Quantity (H) Value ² (I)			
Export shipments: ³ Quantity (J)			
Value (K)			
End-of-period inventories (quantity) (L)			

² Internal consumption and transfers to related firms must be valued at fair market value. If your firm uses a different basis for valuing these transactions in your records, please specify that basis (e.g., cost, cost plus, *etc.*):

______. However, the data provided above in this table should be based on fair market value.

<u>RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.</u>.--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

		Calendar year	
Reconciliation	2022	2023	2024
B + C - D - F - H - J - L = should equal zero ("0") or			
provide an explanation. ¹	0	0	0

¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:_____.

³ Identify your firm's principal export markets: _____.

II-9. <u>Channels of distribution</u>.--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S.-produced MDI products by channel of distribution during the specified periods.

Quantity (in	short tons)		
	Calendar year		
Item	2022	2023	2024
Channels of distribution:			
U.S. shipments:			
To distributors (M)			
to Distillers and processors (N)			
To end users (O)			

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines M, N, and O) in each time period equal the quantity reported for U.S. shipments (i.e., line D, F, H) in each time period. If the calculated fields below return values other than zero (i.e., "O"), the data reported must be revised prior to submission to the Commission.

		Calendar year	
Reconciliation	2022	2023	2024
M + N + O - D - F - H = zero ("0"), if not revise.	0	0	0

II-10. <u>U.S. shipments by type:</u>--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S. produced U.S. shipments of MDI products by type (for usage) during the specified year.

Quantity (in	short tons)
ltem	Calendar year 2024
U.S. shipments for:	
Rigid polyurethane foams (P)	
Flexible polyurethane foams (Q)	
Surface coating applications (R)	
Adhesives and sealants (S)	
Elastomers (T)	
Other known uses (U) ¹	
Unknown uses (V) ²	

¹ Please list the other known uses: _____.

<u>RECONCILIATION OF U.S. SHIPMENTS BY PRODUCT TYPE AND USAGE</u>.--Please ensure that the quantities reported for U.S. shipments by product type and form (i.e., lines P, Q, R, S, T, U, and V) in 2024 equal the quantities and values reported for U.S. shipments (i.e., lines D though H) in 2024. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year
Reconciliation	2024
Quantity: P + Q + R + S + T + U + V - D – F - H = zero ("0"), if not revise.	0

² Please list the top five customers to which you sold your firm's MDI products but for which you do not know the likely ultimate end use application(s) in descending order of your 2024 shipments to them:

II-11. <u>U.S. shipments by form:</u>--Report your firm's U.S. produced U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of MDI products by form during the specified year.

Quantity (short tons) and Value (dollars)	
Item	Calendar year 2024
U.S. shipments: ¹	
Crude polymeric MDI:	
Quantity (W)	
Value (X)	
Pure monomeric MDI:	
Quantity (Y)	
Value (Z)	
All other MDI products (e.g., non-pure, non-crude MDI	
derivatives)¹:	
Quantity (AA)	
Value (AB)	
¹ These products can include MDI that has been partially reacted or polyamines) to remove some but not all isocyanates groups (e	

¹ These products can include MDI that has been partially reacted (e.g., with itself, polyol, or polyamines) to remove some but not all isocyanates groups (e.g., homopolymer, uretonimine MDI, carbodiimide MDI, or prepolymers). Please list the specific other MDI products included in this category, in order of their commercial importance (shipment volumes): _____.

<u>RECONCILIATION OF U.S. SHIPMENTS BY PRODUCT FORM.</u>--Please ensure that the quantities and values reported for U.S. shipments by product form (i.e., lines W, X, Y, Z, AA, and AB) in 2024 equal the quantities and values reported for U.S. shipments (i.e., lines D though J) in 2024. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year
Reconciliation	2024
Quantity: W + Y + AA - D – F - H = zero ("0"), if not revise.	0
Value: $X + Z + AB - E - G - I = zero$ ("0"), if not revise.	0

Explanation of trends:

II-12. <u>Employment data</u>.--Report your firm's employment-related data related to the production of MDI products in your U.S. establishments and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods.

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

		Calendar year	
Item	2022	2023	2024
Average number of PRWs (number)			
Hours worked by PRWs (1,000 hours)			
Wages paid to PRWs (dollars)			

.3.	<u>Transfers to related firms</u> If your firm reported transfers to related firms in question II-8, please identify the firm(s) and indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.
-----	---

II-14.	<u>Purchases</u> Has your firm purchased MDI products produced in the United States or in other
	countries since January 1, 2022? (Do not include imports for which your firm was the importer
	of record. These should be reported in an importer questionnaire.)

"Purchase" – A transaction to buy product from a U.S. corporate entity such as another U.S. producer, a U.S. distributor, or a U.S. firm that has directly imported the product.

"Import" —A transaction to buy from a foreign supplier where your firm is the importer of record.

No	If yesReport such purchases in the table below and explain the reasons for your firms' purchases.

Note: If your firm served as the importer of record for any purchases from foreign suppliers, either for your own account or as a service for another entity, those purchases are to be considered "imports" not "purchases" and **should not** be included in the table below

(Quantity in short tons)						
	Calendar year					
Item	2022	2023	2024			
Purchases from U.S. importers of MDI products						
from—						
China						
All other sources ¹						
Purchases from all sources	0	0	0			
Purchases from domestic producers ²						
Purchases from other sources ³						
 Please list the name of the nonsubject importer(s) fr Please list the name of the U.S. producer(s) from wh Please list the name of the firm(s) from which your f 	ich your firm purcl	nased this product:				

II-15. <u>Purchases of imports from subject sources</u>.--If your firm reported purchases from U.S. importers of MDI products from China at any time since January 1, 2022, report those purchases by the individual importer of record and subject source.

Purchases of subject imports

Quantity (in short tons)					
		Calendar year			
Importer of record	2022	2023	2024		
Grand total:	0	0	0		

<u>RECONCILIATION OF PURCHASES FROM SUBJECT SOURCES</u>.--Please ensure that the quantities reported for your firms purchases of imports from subject sources reported in this question (i.e., "total purchases of imports from subject sources") in each time period equal the quantity reported for your firm's purchases from subject sources in each time period in the previous question. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

		Calendar year	
Reconciliation	2022	2023	2024
Purchases from subject sources in this table – purchases from subject sources in previous			
table = zero ("0"), if not revise.	0	0	0

II-16. Imports.--Since January 1, 2022, has your firm imported MDI products?

"Importer" – The person or firm primarily liable for the payment of any duties on the merchandise, or an authorized agent acting on his behalf.

No	Yes		
		If yesCOMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE	

II-17.	Other explanationsIf your firm would like to further explain a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.

SEC Form 20-F Other (specify):

PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to Zahra Bekkal (202-205-2684)

Title Email Telephone	Name	2					
Accounting system.—Briefly describe your firm's financial accounting system. A.1. When does your firm's fiscal year end (month and day)? If your firm's fiscal year changed since January 1, 2022, explain below: A.2. Note: Calendar-year data are preferred/required for the annual-year financial dath this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provided at a on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for verification firms prepare profit/loss statements for MDI products:	Title						
Accounting system.—Briefly describe your firm's financial accounting system. A.1. When does your firm's fiscal year end (month and day)? If your firm's fiscal year changed since January 1, 2022, explain below: A.2. Note: Calendar-year data are preferred/required for the annual-year financial dath this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provided ata on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar year). Calendar-year basis Fiscal-year basis (does not align with the calendar year). Describe the lowest level of operations (e.g., plant, division, company-wide) for we financial statements are prepared that include MDI products:	Email						
 A.1. When does your firm's fiscal year end (month and day)? If your firm's fiscal year changed since January 1, 2022, explain below: A.2. Note: Calendar-year data are preferred/required for the annual-year financial dath this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provided data on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar basis) Calendar-year basis Fiscal-year basis (does not align with the calendar basis) Calendar-year basis Fiscal-year basis (does not align with the calendar basis) Calendar-year basis Fiscal-year basis (does not align with the calendar basis) Calendar-year basis Fiscal-year basis (does not align with the calendar basis) Calendar-year basis Describe the lowest level of operations (e.g., plant, division, company-wide) for we financial statements are prepared that include MDI products: Does your firm prepare profit/loss statements for MDI products: 	Telep	hone					
A.2. Note: Calendar-year data are preferred/required for the annual-year financial dath this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provided data on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for we financial statements are prepared that include MDI products: B.2. Does your firm prepare profit/loss statements for MDI products:	Accou	nting system.—Briefly descr	ribe your firm's fir	nancial accou	ınting system	1.	
A.2. Note: Calendar-year data are preferred/required for the annual-year financial dath this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provided data on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for verification from the products: Does your firm prepare profit/loss statements for MDI products:	A.1.	•		• •			
this section (i.e., in questions III-9a, III-9d, III-12a, and III-13a). However, if provid data on a calendar-year basis is unduly burdensome or provides results that are reliable, fiscal-year based data are acceptable (please ensure that the majority of fiscal-year end data reported are in the year indicated). Please indicate whether the results in this section are provided on a calendar-year basis (including firms with calendar-year based fiscal year) or on a fiscal-year basis that does not align with the calendar year. Calendar-year basis Fiscal-year basis (does not align with the calendar Describe the lowest level of operations (e.g., plant, division, company-wide) for we financial statements are prepared that include MDI products: B.2. Does your firm prepare profit/loss statements for MDI products:		If your firm's fiscal year ch	anged since Janua	ary 1, 2022, 6	explain below	/ :	
 B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for we financial statements are prepared that include MDI products: B.2. Does your firm prepare profit/loss statements for MDI products: 		reliable, fiscal-year based fiscal-year end data report results in this section are p calendar-year based fiscal	data are acceptab ted are in the yea provided on a cale	ole (please er r indicated). endar-year ba	nsure that the Please indica asis (including	e majority of te whether t g firms with	the the a
financial statements are prepared that include MDI products: B.2. Does your firm prepare profit/loss statements for MDI products:		Calendar-year basis	Fiscal-year b	asis (does no	ot align with t	the calendar	yea
	B.1.			•		y-wide) for w	vhich
	B.2.	_ ' ' ' '		nts for MDI p	oroducts:		
B.3. Please indicate the type and frequency (if applicable) of financial statements prepay by your firm. Please check relevant items below.	B.3.				financial stat	ements prep	oare
Frequency							
Check all Semi-					Frequ		

B.4. Please indicate the primary accounting basis used by your firm.

Accounting basis	Check one
U.S. GAAP	
IFRS	
Tax – cash	
Tax – accrual	
Other (specify):	

3.	<u>Cost accounting system.</u> —Briefly describe your firm's cost accounting system (e.g., standard cost, job order cost, etc.).

III-4. **Product listing.**—Please list the products your firm produces in the facilities in which it produces MDI products and provide the share of net sales accounted for by these products in 2024.

Products	Share of sales in 2024
MDI products	%
	%
	%
	%
	%

U.S. Pr	oducers' Qu	iestionnai	re – MDI Pro	oducts (Preliminary)		Page 27
III-5.	III-5. <u>Inputs from related suppliers.</u> —Does your firm purchase inputs (raw materials, labor, energy or any services) used in the production of MDI products from any related suppliers (e.g., inclusive of transactions between related firms, divisions and/or other components within th same company)?					suppliers (e.g.,
	YesCo	ontinue to	question III	-6. NoContinue to	question III-8	a.
III-6.	products t	hat your f	irm purchas	-Please identify the inputs us es from related suppliers and ease report this information	d that are refl	ected in question III-
	Input			Related supplier		Share of total COGS in 2024
						%
						%
						%
						%
	the narrat	ive box.	Purchase c	ost valuation method		Check all that apply
Related supplier's cost						
	Cost plu					
	Negotiated transfer price to approximate fair market value			e		
	Other (specify):					
	If the methods used differ by input, please describe:					
III-7b.	purchased	from rela	ted supplier	es, as identified in III-6, were consistent with the firm's accordance.	reported in II	I-9a (financial results
	Yes	No	If no—Provin question	vide an explanation and the v	valuation bas	is used for these inputs
		1	1			

U.S. Producers	Questionnaire - MDI Products	(Preliminary)
----------------	------------------------------	---------------

III-8a. Cost assignment/allocation basis.—Briefly describe the assignment/allocation bases used by your firm to assign the costs and expenses listed below for MDI products in the normal course of business and in the financial results reported in question III-9a (e.g., actual costs, standard costs, percentage of COGS, percentage of sales, etc.).

	Assignment/allocation bases used for MDI products—			
Cost/expense	In the normal course of business	In the financial results at III-9a		
Raw materials				
Direct labor				
Other factory costs				
SG&A expenses				
Interest expense				
Other income/expenses				

III-8D.	product items produced during the course of producing MDI products.
	Co-product – For our purposes, this means revenues and costs are kept fully separate from those for MDI products.
	By-product – For our purposes, this means revenues and costs are not kept fully separate from those for MDI products (e.g., revenues may be recorded as an offset to COGS for MD products, or as "other income" MDI products, etc.).

If your answer is "by-product", report the revenues associated with the sale or transfer of the by-product for your firm's three specified full years, and for the specified interim periods.

Note: the data provided below will appear in question III-9b as a reduction to COGS

	Value (in \$1,000)		
		Calendar year	
Item	2022	2023	2024
By-product sales revenue ¹			
By-product sales revenue ¹ ¹ Please describe how your firm classif	ios rovanua from salos	of by product itoms i	in the ner

¹ Please describe how your firm classifies revenue from sales of by-product items in the normal course of business (e.g., included in net sales values of MDI products, as a reduction to COGS of MDI products, included in "all other income" of MDI products): ______.

III-9a. Operations on MDI products.—Report the revenue and related cost information requested below on the MDI products operations of your firm's U.S. establishment(s). Include only sales (whether domestic or exports) and costs related to your U.S. manufacturing operations. Do not report any revenue or cost data related to the resale of purchased product.

Net sales—Report all commercial sales, internal consumption, and transfers to related firms, whether these are domestic sales or exports. Report net sales values less discounts, returns, allowances, and prepaid freight, in U.S. dollars, f.o.b. your point of shipment. The freight costs associated with delivering the product to your customer should not be included.

Note: If the financial data are reported on a calendar-year basis, the total net sales quantities and values should match the total shipment quantities and values reported in Part II of this questionnaire (see question III-14 for a reconciliation grid).

Internal consumption—Product consumed internally by your firm. Report internal consumption at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Transfers to related firms—Sales made to related firms. Report transfers to related firms at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Costs and expenses—Include costs and expenses associated with all reported net sales (i.e., for both domestic and export commercial sales, internal consumption, and transfers to related firms). If any freight costs were removed from net sales values, ensure the associated costs are removed from the applicable cost/expense line.

Inputs from related suppliers—Any inputs purchased from related suppliers should be reported in a manner consistent with your firm's accounting books and records.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the financial data, as Commission staff may contact your firm regarding questions on the financial data. The Commission may also request that your company submit copies of the supporting documents/records (financial statements, including internal profit-and-loss statements for the division or product group that includes MDI products, as well as specific statements and worksheets) used to compile these data.

III-9a. **Operations on MDI products**.—**Continued**

Quantity (in short tons) and value (in \$1,000)			
	Years		
Item	2022	2023	2024
Net sales quantities:			
Commercial sales			
Internal consumption			
Transfers to related firms			
Total net sales quantities	0	0	0
Net sales values: Commercial sales			
Internal consumption			
Transfers to related firms			
Total net sales values	0	0	0
Cost of goods sold (COGS): Raw materials			
Direct labor			
Other factory costs			
Total COGS	0	0	0
Gross profit or (loss)	0	0	0
SG&A expenses			
Operating income (loss)	0	0	0
Other expenses and income: Interest expense			
All other expense items			
All other income items			
Net income or (loss) before income taxes	0	0	0

III-9b. <u>Financial data reconciliation</u>.-- Certain line items from question III-9a, including total net sales quantities and values, total COGS, gross profit (or loss), operating profit (or loss), and net income (or loss), have been calculated based on the data submitted for other line items. Are the data in these calculated line items correct according to your firm's financial records ignoring non-material differences that may arise due to rounding?

Yes	No	If, after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated line items persist, please identify and discuss the differences in the space below.
		Also, check signs accorded to the post operating income line items. The two expense line items should report positive numbers (i.e., expenses are positive, and incomes or reversals are negative in these lines – instances of the latter should be rare in these lines). The income line item should also, in most instances, be a positive number (i.e., income is positive, and expenses or reversals are negative in this line).
		If noIf the calculated line items do not show the correct data, please double check the feeder data for data entry errors and revise.

III-9c. Raw materials.—Please report the share of total raw material costs in 2024 (reported in III-9a) for the following raw material inputs:

		Procureme	ent method
Input	Share of total raw material costs (percent)	Primarily produced by your firm	Primarily purchased by your firm
Aniline ¹			
Formaldehyde ²			
Other raw material inputs ³			
Total (should sum to 100 percent)	0.0		
What was the price of your firm's aniline purchases/production in January 2022 in \$1,000 per short ton of aniline (not the per unit RM cost of aniline in MDI products) and the price your firm's aniline purchases/production in December 2024 in \$1,000 per short ton of aniline (not the per unit RM cost of aniline in MDI products What was the price of your firm's formaldehyde purchases/production in January 2022 in \$1,000 per short ton of formalin (not the per unit RM cost of formalin in MDI products) and the price your firm's formaldehyde purchases/production in December 2024 in \$1,000 per short ton of ani formalin line (not the per unit RM cost of formalin in MDI products). If there are notable or significant raw material inputs included within the "other material inputs" category, please list those here and provide the share of the total raw material costs for which they account:			

III-9d. within the reported financial results at question III-9a.

	Years		
Item	2022	2023	2024
Depreciation expense (in \$1,000)			

III-9e.	<u>Depreciation expense classification</u> .—Please indicate the line item(s) within question III-9a (e.g., other factory costs, SG&A expenses, etc.) that include the depreciation expense reported above.

III-10a. Nonrecurring items (charges and gains) included in the MDI products financial results.—Please report all material (significant) nonrecurring items (charges and gains) that are included in the reported results at question III-9a. If a nonrecurring item that is not product-specific was allocated to the results at question III-9a, please report the allocated value, below, rather than the aggregate amount.

Note: The Commission's objective here is to gather information on <u>material (significant)</u> nonrecurring items which impacted the reported financial results for MDI products in question III-9a.

	Years		
Item	2022	2023	2024
		Value (dollars)	
Nonrecurring item 1			
Nonrecurring item 2			
Nonrecurring item 3			
Nonrecurring item 4			
Nonrecurring item 5			
Nonrecurring item 6			
Nonrecurring item 7			

III-10b. Nonrecurring items (charges and gains) included in the MDI products financial results.—In this table, please provide a brief description of each nonrecurring item reported above and indicate the specific line item within question III-9a in which the nonrecurring item is classified.

	Description of the nonrecurring item	Location (i.e., line item) within question III-9a
Nonrecurring item 1		
Nonrecurring item 2		
Nonrecurring item 3		
Nonrecurring item 4		
Nonrecurring item 5		
Nonrecurring item 6		
Nonrecurring item 7		

III-11.	Classification of identified nonrecurring items (charges and gains) in the accounting books and
	records of the company.—If non-recurring items were reported in question III-10 above, please
	identify where your company recorded these items in your accounting books and records in the
	normal course of business, just as responses to question III-10 identify the specific line items in
	question III-9a where these items are reported.

U.S. Producers' Qu	uestionnaire – MD	Products	(Preliminary)
--------------------	--------------------------	----------	---------------

III-12a. <u>Asset values</u>.—Report the total assets (i.e., <u>both current and long-term assets</u>) associated with the production, warehousing, and sale of MDI products. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for MDI products in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with relevant cost allocations used in question III-9a.

Note: Total assets should reflect the <u>net amount of assets</u> (i.e., after any accumulated depreciation and allowances deducted) and should be <u>allocated to MDI products</u> if these assets are also related to other products.

Value (in \$1,000)			
	Years		
Item	2022	2023	2024
Total assets (net)			

	Total assets (net)				
III-12b.	<u>Description of asset values</u> .—asset value during the period; describe the main asset categor	e.g., due to write-offs, i	major purchases, and r	evaluations. Also	
III-13a. <u>Capital expenditures and research and development ("R&D") ex</u> capital expenditures and research and development expenses for					
	Value (in \$1,000)				
			Years		
	Item	2022	2023	2024	
	Capital expenditures				
	R&D expenses				
III-13b.	Description of reported capital significance of your firm's reported, please explain the re	orted capital expenditur			
	-				

III-14a. <u>Data consistency and reconciliation</u>.—The quantities and values of total net sales reported in question III-9a should reconcile with the total shipments reported in question II-8 (including export shipments) for the annual-year periods as long as they are reported on the same calendar-year basis. The interim-period data should reconcile whether the financial data are on a calendar- or fiscal-year basis.

If the calculated fields below return values other than zero (i.e., "0") this indicates the total net sales quantities and values do not match the total shipments quantities and values.

	Years		
Reconciliation	2022	2023	2024
Quantity: Trade data from question II-8 (lines D, F, H, and J) less financial total net sales quantity data from question III-9a, = zero ("0").	0	0	0
Value: Trade data from question II-8 (lines E, G, I, and K) less financial total net sales value data from question III-9a, = zero ("0").	0	0	0

question III-9a, = zero ("0").	0	0			
Is the financial data in que	Is the financial data in question III-9a reported on a calendar-year basis?				
Yes—Complete ques	tion III-14b. No-	 Continue to question I 	II-15.		
III-14b. <u>Data consistency and reconciliation (calendar-year based financial data)</u> .—Do the data in question III-9a reconcile with the data in question II-8 (i.e., the calculated fields are returning zeros in the table above) <u>for all periods</u> ?					
Yes No	If no, please explain.				

III-15.	Effects of imports on investment. — Since January 1, 2022, has your firm experienced any actual
	negative effects on its return on investment or the scale of capital investments as a result of
	imports of MDI products from China?

No	Yes	
		If yes, my firm has experienced actual negative effects as follows:

(check	k as many as appropriate)	(please describe)
	Cancellation, postponement, or rejection of expansion projects	
	Denial or rejection of investment proposal	
	Reduction in the size of capital investments	
	Return on specific investments negatively impacted	
	Other	

III-16. <u>Effects of imports on growth and development</u>.—Since January 1, 2022, has your firm experienced any actual negative effects on its growth, ability to raise capital, or existing development and production efforts (including efforts to develop a derivative or more advanced version of the product) as a result of imports of MDI products from China?

No	Yes	If yes, my firm has experienced actual negative effects as follows:				
	(chec	k as many as appropriate)	(please describe)			
	Rejection of bank loans					
		Lowering of credit rating				
	Problem related to the issue of stocks or bonds					
		Ability to service debt				
		Other				

III-17.	Anticipated effects of imports. — Does your firm anticipate any negative effects due to imports
	of MDI products from China?

No)	Yes	If yes, my firm anticipates negative effects as follows:
Other o	expl	anations.	—If your firm would like to further explain a response to a question in Part

III for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your	
firm had in providing the data in this section.	

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Economist (202-xxx-xxxx, NAME@usitc.gov).

IV-1. <u>Contact information</u>.--Please identify the individual that Commission staff may contact regarding the confidential information submitted in Part IV.

Name	
Title	
Email	
Telephone	

PRICE DATA

- IV-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers since January 1, 2022 of the following products produced by your firm.
 - **Product 1.--** Polymeric MDI, 150-250 centipoise viscosity at 25o C, 30.2-32.5 Isocyanate content in weight percentage, basic commodity grade (e.g., PM-200, PM-200S, Papi 27, Isobind 1088, Lupranate M20, Rubinate 1840, Rubinate M), sold in bulk (e.g., trucks, rail car, ISO tanks, isotainer).
 - Product 2.-- Polymeric MDI, 150-250 centipoise viscosity at 25o C, 30.2-32.5 Isocyanate content in weight percentage, basic commodity grade (e.g., PM-200, PM-200S, Papi 27, Isobind 1088, Lupranate M20, Rubinate 1840, Rubinate M), sold in packages (e.g., totes, drums).
 - **Product 3.--** Polymeric MDI, 585-900 centipoise viscosity at 25o C, 30.3-32.0 Isocyanate content in weight percentage, basic commodity grade (e.g., PM-700, Papi 580N, Lupranate M70, Rubinate 1850), sold in bulk (e.g., trucks, rail car, ISO tanks, isotainer).

Please note that values should be <u>f.o.b.</u>, <u>U.S.</u> <u>point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates).

IV-2a.	During January 2022-December 2024, did your firm produce and sell to unrelated U.S.
	customers any of the above listed products (or any products that were competitive with these
	products)?

YesPlease complete the following pricing data table as appropriate.
NoSkip to question IV-3.

IV-2b. Price data.--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in *short tons* and *actual dollars* (not dollarss).

	Product 1		Product 2		Product 3	
Period of shipment	Quantity	Value	Quantity	Value	Quantity	Value
2022:						
January-March						
April-June						
July-September						
October-						
December						
2023:						
January-March						
April-June						
July-September						
October-						
December						
2024:						
January-March						
April-June						
July-September						
October-						
December						

f.o.b. your firm's U.S. point of shipment. Please subtract any discounts, rebates, and returns from the quarter in which the sale

NoteIf your firm's product does not exactly meet the product specifications but is competitive with the specified product, pro	vide
a description of your firm's product. Also, please explain any anomalies in your firm's reported pricing data.	

a description of your firm's product. Also, please explain any anomalies in your firm's reported pricing data.	
Product 1:	
Product 2:	
Product 3:	

² Pricing product definitions are provided on the first page of Part IV.

IV-2c. <u>Price data checklist.</u>--Please check that the pricing data in question IV-2b have been correctly reported.

Are the price data reported above:	√ if Yes	
In actual dollars (not dollarss) and actual short tons?		
Valued f.o.b. U.S. point of shipment (i.e., exclude U.S. inland transportation costs)?		
Reported net of all discounts, rebates, and returns (deducted from the quarter in which the original sale occurred)?		
Reported for commercial U.S. shipments only (i.e., exclude internal consumption, transfers, and exports)?		
Less than or equal to the quantities and values reported in Part II for commercial U.S. shipments in each period?		
Explanation(s) for any boxes not checked:		
IV-2d. Pricing data methodologyPlease describe the method and the kinds of documents, that were used to compile your price data.	/records	

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the price data, as Commission staff may contact your firm regarding questions on the price data. The Commission may also request that your company submit copies of the supporting documents/records (such as sales journal, invoices, etc.) used to compile these data.

110	Droducors'	Ougstionnairo	- MDI Products	(Droliminary
U.S.	Producers	Questionnaire -	– IVIDI Products	(Preliminary

IV-3.	Price settingHow does your firm determine the prices that it charges for sales of MDI products
	(check all that apply)?

Transaction by transaction	Contracts	Set price lists	Other	If other, describe
		I —		

IV-4. <u>Discount policy</u>.--Please indicate and describe your firm's discount policies (*check all that apply*).

Quantity discounts	Annual total volume discounts	No discount policy	Other	Describe

IV-5. <u>Pricing terms.</u>--On what basis are your firm's prices of domestic MDI products usually quoted *(check one)*?

Delivered	F.o.b.	If f.o.b., specify point

IV-6. <u>Contract versus spot.</u>—Approximately what shares of your firm's sales of its U.S.-produced MDI products in 2024 were on the basis of (1) short-term contracts, (2) annual contracts, (3) long-term contracts, and (4) spot sales?

	Type of sale					
Item	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)	Spot sales (for a single delivery)	Total (should sum to 100.0%	d o
Share of 2024 sales	%	%	%	%	0.0	%

IV-7. <u>Contract provisions.</u>--Please fill out the table regarding your firm's typical sales contracts for U.S.-produced MDI products (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

Typical sales contract provisions	Item	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)		
Average contract duration	No. of days		365			
Price renegotiation	Yes					
(during contract period)	No					
	Quantity					
Fixed quantity and/or price	Price					
3.1.5, 5.1 p.1.55	Both					
Indexed to raw	Yes					
material costs ¹	No					
Not applicable						
¹ Please identify the indexes used:						

IV-8. <u>Lead times.--</u>What share of your firm's sales of its U.S.-produced MDI products was from inventory and produced to order, and what was the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced MDI products?

Source	Share of 2024 sales	Lead time (Average number of days)
From inventory	%	
Produced to order	%	
Total (should sum to 100.0%)	0.0 %	

(b)

IV-9.	Shippin	g information
	(a)	Who generally arranges the transportation to your firm's customers' locations? Your firm Purchaser (check one)

Indicate the approximate percentage of your firm's sales of MDI products that are

0.0 %

Distance from production facility	Share
Within 100 miles	%
101 to 1,000 miles	%
Over 1,000 miles	%

delivered the following distances from its production facility.

Total (should sum to 100.0%)

IV-10. <u>Geographical shipments.</u>—In which U.S. geographic market area(s) has your firm sold its U.S.-produced MDI products since January 1, 2022 (check all that apply)?

Geographic area	√ if applicable
Northeast.–CT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
Midwest.–IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central Southwest.—AR, LA, OK, and TX.	
Mountains.—AZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific Coast.–CA, OR, and WA.	
Other.—All other markets in the United States not previously listed, including AK, HI, PR, and VI.	

IV-11.	<u>Inland transportation costs.</u> —What is the approximate percentage of the cost	t of U.Sproduced
	MDI products that is accounted for by U.S. inland transportation costs?	percent

IV-13. **Substitutes.--**Can other products be substituted for MDI products?

IV-12. <u>End uses.</u>--List the end uses of the MDI products that your firm manufactures. For each end-use product, what percentage of the <u>total cost</u> is accounted for by MDI products and other inputs?

	Share of total cost of end use product accounted for by		Total
End-use product	MDI products	Other inputs	(should sum to 100.0% across)
	%	%	0.0 %
	%	%	0.0 %
	%	%	0.0 %

		End use in which this			nanges in the price of this substitute cted the price for MDI products?
	Substitute	substitute is used	No	Yes	Explanation
1.					
2.					
3.					

Select one box per row.

Market	Steadily increase	Fluctuate up	No change	Fluctuate down	Steadily decrease	Explanation and factors
Within the United States						
Outside the United States						

U.S. Pro	oducers' Qu	estionnaii	re – MDI Products (Preliminary) Page 46
IV-15.			lave there been any significant changes in the product range, product mix, products since January 1, 2022?
	No	Yes	If yes, please describe and quantify if possible.
IV-16.			the MDI products market subject to business cycles, either during the year es, describe.
	No	Yes	If yes, please describe, including any changes since January 1, 2022.
IV-17.		to MDI pr	etitionIs the MDI products market subject to conditions of competition oducts other than the business cycles described in the previous question? If
	No	Yes	If yes, please describe, including any changes since January 1, 2022.

IV-18.	Supply	constraints.—
--------	--------	---------------

(a) Has your firm refused, declined, or been unable to supply MDI products at any time since January 1, 2022 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, being unable to meet timely shipment commitments, impact from changes in operations listed in II-2a, etc.)?

No (skip to IV-19)	Yes (respond to part b)

(b) For each year that your firm faced supply constraints, describe the constraints with the details requested below.

Check if yes	Period	Description: include the timing, duration, and reason for the constraint.
	2022	
	2023	
	2024	

IV-19. <u>Raw materials</u>.-- Have MDI products raw material prices steadily increased, fluctuated but ended higher, not changed, fluctuated but ended lower, or steadily decreased since January 1, 2022?

Select one box per row.

Steadily increase	Fluctuate up	No change	Fluctuate down	_	Explain, noting how raw material price changes have affected your firm's selling prices for MDI products.

- U.S. Producers' Questionnaire MDI Products (Preliminary)
- IV-20. <u>Interchangeability.</u>—How often are MDI products produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = no familiarity with products from a specified country-pair

Country-pair	China	Other countries
United States		
China		

For any country-pair producing MDI products that is *sometimes* or *never* interchangeable, identify the country-pair and explain the factors that limit or preclude the interchangeable use of MDI products produced in the countries:

IV-21. <u>Factors other than price</u>.—How often are differences other than price (e.g., quality, availability, transportation network, product range, technical support, *etc.*) between MDI products produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

- A = such differences are *always* significant
- F = such differences are *frequently* significant
- S = such differences are *sometimes* significant
- N = such differences are *never* significant
- 0 = *no familiarity* with products from a specified country-pair

Country-pair	China	Other countries
United States		
China		

For any country-pair for which factors other than price are *always* or *frequently* a significant factor in your firm's sales of MDI products, identify the country-pair and the relevant factors other than price, and report the advantages or disadvantages imparted by such factors:

IV-22.	Role of section 301 tariffs Did the tariffs on Chinese-origin products under section 301, o
	changes in these tariffs, have an impact on the MDI products market in the United States,
	including any effects on MDI products cost, price, supply, and/or demand, since January 1,
	20222

Yes	No	Don't know				
If yes, please describe the impact on cost, price, supply, and/or demand, and include the timing of such impacts.						

IV-23. <u>Customer identification</u>.--List the names and contact information for your firm's 10 largest U.S. customers for MDI products since January 1, 2022. Indicate the share of the quantity of your firm's U.S. shipments of MDI products that each of these customers accounted for in 2024.

Cu	stomer's name	Contact person	Email	Telephone	City	State	Share of 2024 sales (%)
1							
2							
3							
4							
5							
6							
7							
8							
9							
10							

U.S. Producers	' Questionnaire -	- MDI Products	(Preliminary)
----------------	-------------------	----------------	---------------

IV-24.	Com	petition	from	imp	orts

(a) <u>Lost revenue</u>.--Since January 1, 2022: To avoid losing sales to competitors selling MDI products from China, did your firm:

Item	No	Yes
Reduce prices		
Roll back announced price increases		

(b) <u>Lost sales.</u>--Since January 1, 2022: Did your firm lose sales of MDI products to imports of this product from China?

No	Yes	

(c) The submission of lost sales/lost revenue allegations is to be completed only by NON-PETITIONERS.

If your firm indicated "yes" to any of the above, your firm can provide the Commission with additional information by downloading and completing the lost sales/lost revenues worksheet at http://usitc.gov/trade_remedy/question.htm. Note that the Commission may contact the firms named to verify the allegations reported.

Is your firm submitting the lost sales/lost revenues worksheet?

No—Please explain.
Yes—Please complete the worksheet and submit via the Commission dropbox.
https://dropbox.usitc.gov/oinv/. (select Lost Sales-Lost Revenues)

IV-25.	Other explanationsIf your firm would like to further explain a response to a question in Part
	IV for which a narrative response box was not provided, please note the question number and
	the explanation in the space provided below. Please also use this space to highlight any issues
	your firm had in providing the data in this section.

PART V.—<u>ALTERNATIVE PRODUCT INFORMATION</u>

Further information on this part of the questionnaire can be obtained from Lawrence Jones (202-205-3358, lawrence.jones@usitc.gov).

- V-1. Comparability of alternative products.-- For each of the following indicate whether listed MDI products are: fully comparable or the same, *i.e.*, have no differentiation between them; mostly comparable or similar; somewhat comparable or similar; never or not-at-all comparable or similar; or no familiarity with products.
 - F: fully comparable or the same, i.e., have no differentiation between them;

M: mostly comparable or similar;

S: somewhat comparable or similar;

N: never or not-at-all comparable or similar; or

0: no familiarity with products.

(a) <u>Physical Characteristics and End Uses</u>.--The differences and similarities in the physical characteristics and end uses.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>physical characteristics and uses</i> :
MDI products vs. toluene di-isocyanate (TDI)		

(b) <u>Interchangeability</u>.--The ability to substitute the products in the same application.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>interchangeability</i> :
MDI products vs. toluene di-isocyanate (TDI)		

(c) <u>Channels of distribution</u>.--Channels of distribution/market situation through which the products are sold (i.e., sold direct to end users, through wholesaler/distributors, etc.).

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>channels of distribution</i> :
MDI products vs. toluene di-isocyanate (TDI)		

V-1. Comparability of alternate products.--Continued

F: fully comparable or the same, i.e., have no differentiation between them;

M: mostly comparable or similar;

S: somewhat comparable or similar;

N: never or not-at-all comparable or similar; or

0: no familiarity with products.

(d) <u>Manufacturing facilities, production processes, and production employees</u>.--Whether manufactured in the same facilities, from the same inputs, on the same machinery and equipment, and using the same employees.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <u>manufacturing facilities</u> , <u>production</u> <u>processes</u> , <u>and production employees</u> :
MDI products vs. toluene di-isocyanate (TDI)		

(e) <u>Customer and producer perceptions</u>.--Perceptions as to the differences and/or similarities in the market (*e.g.*, sales/marketing practices).

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>customer and producer perceptions</i> :
MDI products vs. toluene di-isocyanate (TDI)		

(f) **Price**.--Whether prices are comparable or differ between the products.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>price</i> :
MDI products vs. toluene di-isocyanate (TDI)		

Email Telephone

PART VI.—SUFFICIENT PRODUCTION RELATED ACTIVITIES ANALYSIS

Further information on this part of the questionnaire can be obtained from Lawrence Jones (202-205-3358, lawrence.jones@usitc.gov).

VI-1.	<u>Contact information</u> Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in Part VI.			
	Name			
	Title			

VI-2.	Explanation of firm's domestic activities. —Please describe in detail your firm's domestic
	production operations relating to MDI products, including, if applicable, incorporation of
	imported or purchased MDI products, either domestic or imported, that is processed/converted
	into another in-scope form of MDI products in the United States prior to commercial sale.

VI-3.	Domestic activities by factor . —Please describe the nature and extent of the following items in
	relation to your firm's U.S. production of MDI products in the United States.

Capital investments	
Technical expertise	
Value added	
Employment	
Quantity, type, and source of parts	
Costs and activities	

110	Droducars'	Questionnaire -	MDI Products	(Proliminary)
U.S.	Producers	Questionnaire -	- IVIDI Products	terenminary

VI-4.	Operations' complexity and importance . —On a scale of 1 to 5, please provide your firm's
	subjective opinion as to the complexity, intensity, and importance of your firm's MDI products'
	operations conducted in the United States, with 1 being minimally complex, intense, or
	important and 5 being extremely complex, intense, or important.

1: Minimally complex, intense, and important	2	3	4	5: Extremely complex, intense, and important
Please describe the reason for your rating below.				

VI-5. <u>Greenfield capital investment costs</u>.--Indicate the estimated amount of capital investment that would be required today on a greenfield basis to replicate your firm's current MDI products operations.

Item	Value (in \$1,000)
Estimated greenfield capital investment cost of current	
U.S. MDI products operations	

VI-6. Top three MDI products using purchased/imported MDI products.--If your firm purchased and/or imported an in-scope MDI products, processed that product domestically in the United States, and sold that further processed product that still matches the definition of MDI products (see p. 2), please list the top three MDI products your firm sold, provide an indication of their formulation(s), and describe how those products are marketed in the United States.

Not applicable	Yes applicable	If yes, please list the top three MDI products products your firm sold, provide an indication of their formulation(s), list the inputs (raw materials), and describe how those products are marketed in the United States.

Page 56

PART VII.—PROCESSING OPERATIONS

Further information on this part of the questionnaire can be obtained from Lawrence Jones (202-205-3358, lawrence.jones@usitc.gov).

<u>Processing.</u>--Your firm purchases or otherwise procures in-scope MDI products from another entity (i.e., either domestically manufactured or imported MDI products), and your firm conducts further processing of those already in-scope MDI products into another form of inscope product (e.g., import crude polymeric MDI and process it into pure monomeric MDI) in the United States.

VII-1a. <u>Contact information.</u>--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in Part VII.

Name	
Title	
Email	
Telephone	

VII-1b. <u>Processing activities</u>.--Did your firm process both in-scope MDI products and out-of-scope products (e.g., TDI products, et cetera)?

No	Yes	If yes, please ensure you only include data on those operations that result in an end product that your firm sells that still matches the definition of MDI products (i.e., is still in-scope), and explain here how your firm allocated any of its data from its overall operations to just the in-scope portion of its operations for the information reported in this part of the questionnaire.

VII-1c. Purchases and/or imports of MDI products for use in domestic processing operations: If your firm purchased and/or imported MDI products for purposes of processing/converting that product into another in-scope form in the United States, please report the quantity and value of such purchases and/or imports used for this processing activity during the specified periods.

(Quantity in short tons) and value (in \$1,000)				
	Calendar year			
Item	2022	2023	2024	
Purchases/imports of MDI products for processing activities in the United States				
from:				
Domestic sources ¹ :				
Quantity				
Value				
Subject sources ¹ : Quantity				
Value				
Nonsubject sources ¹ : Quantity				
Value				
¹ Please list the specific MDI inputs that your firm purchased:				

VII-2. <u>Processing, shipments, and inventory data.</u>--Report your firm's practical capacity, processing, shipments, and inventories of domestically processed MDI products during the specified periods.

"Processing" – All processing in your U.S. establishment(s), including processing consumed internally within your firm and processing for another firm under a toll agreement.

"Commercial U.S. shipments" – Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" — Processed goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as processing and sales schedules, inventory records, etc.) used to compile these data.

Processing, shipment, and inventory data.--Continued

Calendar vear		
2022	2023	2024
		Calendar year 2022 2023

[.] However, the data provided above in this table should be based on fair market value.

RECONCILIATION OF SHIPMENTS, PROCESSING, AND INVENTORY.--Generally, the data reported for the end-of-period inventories (i.e., line N) should be equal to the beginning-of-period inventories (i.e., line B), plus processing (i.e., lines C, D, and E), less total shipments (i.e., lines F, H, J, and K). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

	Calendar year			
Reconciliation	2022	2023	2024	
B + C + D + E - F - H - J - K - N = should equal zero				
("0") or provide an explanation.1	0	0	0	

¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:____

³ Identify your firm's principal export markets: _

VII-3. <u>Channels of distribution</u>.--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S.-processed MDI products by channel of distribution during the specified periods.

Quantity (in short tons)				
Calendar year				
Item	2022	2023	2024	
Channels of distribution: U.S. shipments:				
To distributors (O)				
to Distillers and processors (P)				
To end users (Q)				

<u>RECONCILIATION OF CHANNELS.</u>--Please ensure that the quantities reported for channels of distribution (i.e., lines O, P, and Q) in each time period equal the quantity reported for U.S. shipments (i.e., line F, H, J) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

		Calendar year	
Reconciliation	2022	2023	2024
O + P + Q - F - H - J = zero ("0"), if not revise.	0	0	0

VII-4. <u>U.S. shipments by type:</u>--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S. processed U.S. shipments of MDI products by type (for usage) during the specified year.

Quantity (in short tons)				
Item	Calendar year 2024			
U.S. shipments for:				
Rigid polyurethane foams (R)				
Flexible polyurethane foams (S)				
Surface coating applications (T)				
Adhesives and sealants (U)				
Elastomers (V)				
Other known uses (W) ¹				
Unknown uses (X) ²				

¹ Please list the other known uses: _____.

<u>RECONCILIATION OF U.S. SHIPMENTS BY PRODUCT TYPE AND USAGE</u>.--Please ensure that the quantities reported for U.S. shipments by product type and form (i.e., lines R, S, T, U, V, W, and X) in 2024 equal the quantities and values reported for U.S. shipments (i.e., lines F though J) in 2024. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year
Reconciliation	2024
Quantity: R + S + T + U + V + W + X - F - H - J = zero ("0"), if not revise.	0

² Please list the top five customers to which you sold your firm's MDI products but for which you do not know the likely ultimate end use application(s) in descending order of your 2024 shipments to them:

VII-5. <u>U.S. shipments by form:</u>--Report your firm's U.S. processed U.S. shipments of MDI products by form during the specified year.

Quantity (<i>short tons</i>) and Value (dollars)			
Item	Calendar year 2024		
U.S. shipments:1			
Crude polymeric MDI:			
Quantity (Y)			
Value (Z)			
Pure monomeric MDI:			
Quantity (AA)			
Value (AB)			
All other MDI products (e.g., non-pure, non-crude MDI			
derivatives)¹:			
Quantity (AC)			
Value (AD)			

¹ These products can include MDI that has been partially reacted (e.g., with itself, polyol, or polyamines) to remove some but not all isocyanates groups (e.g., homopolymer, uretonimine MDI, carbodiimide MDI, or prepolymers). Please list the specific other MDI products included in this category, in order of their commercial importance (shipment volumes): _____.

<u>RECONCILIATION OF U.S. SHIPMENTS BY PRODUCT FORM.</u>.--Please ensure that the quantities and values reported for U.S. shipments by product form (i.e., lines Y, Z, AA, AB, AC, and AD) in 2024 equal the quantities and values reported for U.S. shipments (i.e., lines F though L) in 2024. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year	
Reconciliation	2024	
Quantity: Y + AA + AC - F – H - J = zero ("0"), if not revise.	0	
Value: $Z + AB + AD - E - G - I = zero$ ("0"), if not revise.	0	

VII-6. <u>Employment data</u>.--Report your firm's employment-related data related to the processing of MDI products in your U.S. establishments and provide an explanation for any trends in these data.

"Processing and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary processing for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above processing operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods.

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

	Calendar year		
Item	2022	2023	2024
Average number of PRWs (number)			
Hours worked by PRWs (1,000 hours)			
Wages paid to PRWs (dollars)			

E	xplanation of trends:			

VII-7. Operations on processing activities.—Report the revenue and related cost information requested below on the processing of MDI products of your firm's U.S. establishment(s). Include only sales (whether domestic or exports) and costs related to your U.S. manufacturing operations. Do not report any revenue or cost data related to the resale of purchased product.

Net sales—Report all commercial sales, internal consumption, and transfers to related firms, whether these are domestic sales or exports. Report net sales values less discounts, returns, allowances, and prepaid freight, in U.S. dollars, f.o.b. your point of shipment. The freight costs associated with delivering the product to your customer should not be included.

Note: If the financial data are reported on a calendar-year basis, the total net sales quantities and values should match the total shipment quantities and values reported in this section of the questionnaire (see question VII-11a for a reconciliation grid).

Internal consumption—Product consumed internally by your firm. Report internal consumption at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Transfers to related firms—Sales made to related firms. Report transfers to related firms at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

Costs and expenses—Include costs and expenses associated with all reported net sales (i.e., for both domestic and export commercial sales, internal consumption, and transfers to related firms). If any freight costs were removed from net sales values, ensure the associated costs are removed from the applicable cost/expense line.

Inputs from related suppliers—Any inputs purchased from related suppliers should be reported in a manner consistent with your firm's accounting books and records.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the financial data, as Commission staff may contact your firm regarding questions on the financial data. The Commission may also request that your company submit copies of the supporting documents/records (financial statements, including internal profit-and-loss statements for the division or product group that includes processing of MDI products, as well as specific statements and worksheets) used to compile these data.

VII-7. Operations on processing activities.—Continued

Quantity	y (in short tons) and va	lue (<i>in \$1,000</i>)	
	Years		
Item	2022	2023	2024
Net sales quantities: ²			
Commercial sales			
Internal consumption			
Transfers to related firms			
Total net sales quantities	0	0	0
Net sales values: Commercial sales			
Internal consumption			
Transfers to related firms			
Total net sales values	0	0	0
Cost of goods sold (COGS): MDI products.— Domestically manufactured			
Foreign investigated sources ¹			
Foreign non-investigated sources ¹			
All other raw materials ²			
Total raw material costs	0	0	0
Direct labor			
Other factory costs			
Total COGS	0	0	0
Gross profit or (loss)	0	0	0
SG&A expenses			
Operating income (loss)	0	0	0
Other expenses and income: Interest expense			
All other expense items			
All other income items			
Net income or (loss) before			
income taxes	0	0	0

¹ In the space provided please identify the relevant foreign source countries (investigated _____and non-investigated: ____).

² If there are notable or significant raw material inputs included within the "All other materials" category, please list those here and provide the share of total raw material costs for which they account: ____.

U.S. Producers	'Questionnaire -	- MDI Products	(Preliminary
----------------	------------------	----------------	--------------

VII-8a. <u>Depreciation expense</u>.—Please report the amount of depreciation expense that is included within the reported financial results at question VI-7.

	Years		
Item	2022	2023	2024
Depreciation expense			
Depreciation expense (in \$1,000)			

VII-8b.	<u>Depreciation expense classification</u> .—Please indicate the line item(s) within question VI-6 (e.g., other factory costs, SG&A expenses, etc.) that include the depreciation expense reported above.

VII-9a. <u>Asset values</u>.—Report the total assets (i.e., <u>both current and long-term assets</u>) associated with the processing, warehousing, and sale of processed MDI products. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for processed MDI products in the normal course of business, please estimate this information based upon a method (such as processing, sales, or costs) that is consistent with relevant cost allocations used in question VI-6.

Note: Total assets should reflect the <u>net amount of assets</u> (i.e., after any accumulated depreciation and allowances deducted) and should be <u>allocated to</u> processed MDI products if these assets are also related to other products.

Value (in \$1,000)			
	Years		
Item	2022	2023	2024
Total assets (net)			

VII-9b.	<u>Description of asset values</u> .—Please provide explanations for any substantial changes in total asset value during the period; e.g., due to write-offs, major purchases, and revaluations. Also describe the main asset categories (both current and long-term) included in the above response.

VII-10a. <u>Capital expenditures and research and development ("R&D") expenses</u>.—Report your firm's capital expenditures and research and development expenses related to its processing of MDI products.

Value (in \$1,000)			
	Years		
Item	2022	2023	2024
Capital expenditures			
R&D expenses			

S	Description of reported capital expenditures.—Please describe the nature, focus, and significance of your firm's reported capital expenditures. If no capital expenditure data were reported, please explain the reason.
_	Description of reported R&D expenses.—Please describe the nature, focus, and significance of your firm's reported R&D expenses.

VII-11a. <u>Data consistency and reconciliation</u>.—The quantities and values of total net sales reported in question VII-7 should reconcile with the total shipments reported in question VII-2 (including export shipments) for the annual-year periods as long as they are reported on the same calendar-year basis. The interim-period data should reconcile whether the financial data are on a calendar- or fiscal-year basis.

If the calculated fields below return values other than zero (i.e., "0") this indicates the total net sales quantities and values do not match the total shipments quantities and values.

	Years		
Reconciliation	2022	2023	2024
Quantity: Trade data from question VII-2 (lines F, H, J, and L) less financial total net sales quantity data from question VI-6, = zero ("0").	0	0	0
Value: Trade data from question VII-2 (lines G, I, K, and M) less financial total net sales value data from question VI-6, = zero ("0").	0	0	0

,	Are the financial data in question VI-6 reported on a calendar-year basis?		
	Yes—Com	nplete question	VI-10b. No— Continue to question VII-12.
(question VII-6	-	liation (calendar-year based financial data).—Do the data in the data in question VII-2 (i.e., the calculated fields are returning the periods?
	Yes	No	If no, please explain.

VII-12. <u>Effects of imports on investment</u>.—Since January 1, 2022, has your firm experienced any actual negative effects on its return on investment or the scale of capital investments as a result of imports of MDI products from China?

No	Yes				
		If yes, my firm has experienced actual negative effects as follows.			
	(checi	k as many as appropriate)	(please describe)		
		Cancellation, postponement, or rejection of expansion projects			
		Denial or rejection of investment proposal			
		Reduction in the size of capital investments			
		Return on specific investments negatively impacted			
		Other			

VII-13.	Effects of imports on growth and development.—Since January 1, 2022, has your firm
	experienced any actual negative effects on its growth, ability to raise capital, or existing
	development and processing efforts (including efforts to develop a derivative or more advanced
	version of the product) as a result of imports of MDI products from China?

No	Yes			
		If yes, my firm has experienced actual negative effects as follows.		
	(chec	k as many as appropriate)	(please describe)	
		Rejection of bank loans		
		Lowering of credit rating		
		Problem related to the issue of stocks or bonds		
		Ability to service debt		
		Other		

VII-14. Anticipated effects of imports.—	Does your firm anticipate any negative effects due to imports
of MDI products from China?	

No	Yes	If yes, my firm anticipates negative effects as follows.

VII-15.	Other explanations.—If your firm would like to further explain a response to a question in the financial section of Part VI for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.

HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://usitc.gov/reports/active import injury questionnaires.

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission of further instructions.

• <u>Upload via Commission's secure submission portal</u>.— The questionnaire must be uploaded in two formats: (1) a Microsoft Word document; and (2) a PDF copy of the complete questionnaire with a signature on the first page. Please include any attachments at the end of the PDF (e.g., APO certification, additional comments, etc.).

Web address: https://usitc.gov/qportal Pin: MDIP Phase: Preliminary

• E-mail.— E-mail the MS Word questionnaire to <u>lawrence.jones@usitc.gov</u>; include a PDF copy of the complete questionnaire with a signature on the first page. Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure submission portal and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm does not produce this product, please fill out page 1, print, sign, and submit a scanned PDF copy via the Commission's secure submission portal or email.

<u>Parties to this proceeding</u>.— If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.